First Hawaiian Bank Sells 3,040 Shares of IQVIA Holdings Inc. (NYSE:IQV)

First Hawaiian Bank lowered its position in IQVIA Holdings Inc. (NYSE:IQV) by 49.9% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,048 shares of the medical research company’s stock after selling 3,040 shares during the quarter. First Hawaiian Bank’s holdings in IQVIA were worth $644,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also bought and sold shares of the company. Rise Advisors LLC purchased a new stake in shares of IQVIA in the 1st quarter valued at $31,000. Riverview Trust Co bought a new stake in IQVIA in the first quarter worth $32,000. Covestor Ltd boosted its position in IQVIA by 45.3% during the first quarter. Covestor Ltd now owns 154 shares of the medical research company’s stock valued at $39,000 after buying an additional 48 shares during the period. Security National Bank bought a new position in shares of IQVIA during the fourth quarter valued at about $41,000. Finally, GAMMA Investing LLC purchased a new position in shares of IQVIA in the fourth quarter worth about $60,000. 89.62% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of brokerages have commented on IQV. Truist Financial lifted their price target on IQVIA from $292.00 to $300.00 and gave the stock a “buy” rating in a research note on Tuesday, July 23rd. StockNews.com upgraded shares of IQVIA from a “hold” rating to a “buy” rating in a report on Monday, July 15th. Evercore ISI raised their price target on shares of IQVIA from $230.00 to $270.00 and gave the stock an “outperform” rating in a report on Tuesday, July 23rd. JPMorgan Chase & Co. lifted their price objective on IQVIA from $260.00 to $288.00 and gave the stock an “overweight” rating in a research report on Monday. Finally, Jefferies Financial Group downgraded IQVIA from a “buy” rating to a “hold” rating and decreased their target price for the company from $266.00 to $242.00 in a report on Wednesday, July 24th. Four investment analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $265.67.

IQVIA Stock Down 3.4 %

NYSE:IQV traded down $8.15 during trading hours on Monday, reaching $233.63. 1,195,182 shares of the company traded hands, compared to its average volume of 1,093,257. The company has a current ratio of 0.85, a quick ratio of 0.85 and a debt-to-equity ratio of 1.80. The business’s 50-day moving average price is $221.77 and its two-hundred day moving average price is $230.63. IQVIA Holdings Inc. has a 1 year low of $167.42 and a 1 year high of $261.73. The stock has a market capitalization of $42.57 billion, a P/E ratio of 31.99, a P/E/G ratio of 2.35 and a beta of 1.49.

IQVIA (NYSE:IQV) last posted its quarterly earnings results on Monday, July 22nd. The medical research company reported $2.64 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.57 by $0.07. The firm had revenue of $3.81 billion during the quarter, compared to analyst estimates of $3.79 billion. IQVIA had a return on equity of 28.59% and a net margin of 9.39%. IQVIA’s quarterly revenue was up 2.3% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.22 EPS. Analysts predict that IQVIA Holdings Inc. will post 10.21 earnings per share for the current year.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.